Ness-Ziona, Israel, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that it will present a late-breaking poster abstract at the American College of Rheumatology (ACR) Convergence 2025, taking place October 24–29 at McCormick Place Convention Center in Chicago, Illinois. The presentation will feature clinical data from the recently announced Phase IIa (ENX-CL-05-001) 3-month topline dat ...

-- Data demonstrates sustained clinical improvements in pain, stiffness and function for up to 156 weeks following a single administration of PCRX-201 -- BRISBANE, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today announced updated three-year results and a new subset analyses demonstrating sustained efficacy and safety across all patient subgroups, including ...

SEATTLE, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the third quarter ended September 30, 2025. Third Quarter 2025 Business Highlights Continued progress was made in processing Tau proteoform samples from collaborators in support of our goals of product validation and growing our publications. We expect to share this data at the upcoming World HUPO confer ...

SAN DIEGO, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced that company management will participate in the below November investor conferences. Details are as follows: Event: Guggenheim 2nd Annual Healthcare Innovation ConferenceDate: November 11, 2025Time: 8:00 AM ETFormat: Fireside Chat Event: Jefferies London Healthcare Conference Date: November 1 ...

GAITHERSBURG, Md., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced the results of a new survey1 of approximately 250 U.S. policy opinion leaders showing that nearly two-thirds (65 percent) of respondents agree the likelihood of a biological attack on U.S. soil is rising, yet almost half (45 percent) believe the U.S. is unprepared for a biological attack. Conducted by Penta Group on behalf of Emergent, the survey amplifies findings in the unclassified 2025 Annual Thre ...

Mr. Quigley most recently led McKinsey & Company’s Private Capital practice and previously led various Life Sciences practices at the firm Appointment adds deep business strategy, transactional, and commercial expertise as CervoMed prepares for Phase 3 and commercialization planning BOSTON, Oct. 28, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO) (CervoMed or the Company), a clinical-stage biotechnology company developing treatments for age-related brain disorders, today announced the appointment of D ...

Core Insights - ARK Invest has reduced its stake in Palantir (NASDAQ: PLTR) despite the stock's impressive performance, which has seen a year-to-date increase of over 150% and a recent peak at $190.84 [1][2] Group 1: Stock Performance - Palantir's stock has surged more than 150% year to date, reaching an all-time high of $190.84, and closing at $189 on the latest trading day [2] - The company's strong fundamentals are reflected in gross profit margins near 80% and a revenue growth of 39% over the past year [4] Group 2: Company Developments - Palantir is expanding its role in artificial intelligence and government data analytics, with its software being utilized in U.S. Army drone tests and forming new partnerships with Lumen Technologies and Snowflake to enhance enterprise adoption of its Foundry platform [5] Group 3: ARK Invest's Strategy - While reducing its position in Palantir, ARK Invest has increased holdings in other companies such as Block, Intellia Therapeutics, 10x Genomics, and Pacific Biosciences, indicating a focus on genomics and innovation [6] - The fund has also added positions in DraftKings, Amazon, Alibaba, and DoorDash, showcasing continued confidence in digital commerce and biotech sectors [6] - ARK has simultaneously reduced positions in other high-growth stocks like Shopify, Roblox, and SoFi Technologies, reflecting a strategy of rebalancing amid market volatility [7]

Accessibility StatementSkip Navigation Pelareorep plus atezolizumab achieves 30% ORR in second-line or later (2L) squamous cell anal carcinoma (SCAC) relative to 13.8% for the FDA-approved 2L treatment The median duration of response was 15.5 months compared to 9.5 months for the current standard of care Company expects to discuss single-arm accelerated approval study with FDA in Q1 2026 SAN DIEGO, Calif., Oct. 28, 2025 /PRNewswire/ -- Oncolytics Biotech Inc. (NASDAQ: ONCY) ("Oncolytics" or the "Company"), ...

沙特阿拉伯利雅得, Oct. 28, 2025 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital and Research Centre (KFSHRC) 宣布，将于 2025 年年底启用沙特阿拉伯首个基因和细胞疗法产品生产基地，旨在为成千上万的患者在本土提供先进的治疗。预计到 2030 年将减少约 80 亿里亚尔（约合 20 亿美元）的医疗费用，并满足全国约 9% 的相关治疗需求。 这座新基地位于医院的利雅得园区内，将专注于 CAR-T 细胞疗法和干细胞疗法的生产，这些疗法通过改造患者自身细胞以对抗癌症或修复受损组织。 该基地的占地面积超过 5,000 平方米，整体设计以 16 个模块化的洁净室集群为中心，可根据新兴治疗技术的发展扩展或调整。 相关官员表示，该综合体基地融合了精准医疗与先进制造，其建成标志着沙特阿拉伯在生物技术领域的一个重要里程碑。 全面投入运行后，预计每年可生产约 2,400 剂治疗药物，提升沙特阿拉伯在全球高端疗法产品生产领域的产能。 该基地将依照药品制造的国际准则框架 GMP 进行运营。 从空气过滤到批次检测的每个环节都将受到监控， ...

Making its debut on 06/19/2006, smart beta exchange traded fund First Trust NYSE Arca Biotechnology ETF (FBT) provides investors broad exposure to the Health Care ETFs category of the market.What Are Smart Beta ETFs?The ETF industry has traditionally been dominated by products based on market capitalization weighted indexes that are designed to represent the market or a particular segment of the market.A good option for investors who believe in market efficiency, market cap weighted indexes offer a low-cost ...